Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients

SAN DIEGO, Sept. 22, 2021 -- (Healthcare Sales & Marketing Network) -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, ... Biopharmaceuticals, Oncology Kintara Therapeutics, glioblastoma multiforme
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news